Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 5
Submit an article Journal homepage
922
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice

Versha Banerjia Paul Albrechtsen Research Institute, CancerCare Manitoba and University of Manitoba, Winnipeg, Manitoba, CanadaCorrespondence[email protected]
View further author information
,
Andrew Awb University of Ottawa, Ottawa, Ontario, CanadaView further author information
,
Nicole Laferrierec Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, CanadaView further author information
,
Nizar Abdel-Samadd Moncton Hospital, Moncton, New Brunswick, CanadaView further author information
,
Anthea Peterse University of Alberta, Edmonton, Alberta, CanadaView further author information
,
Nathalie A. Johnsonf Jewish General Hospital, Montreal, Quebec, CanadaView further author information
,
Marie-Pierre Bernardg Centre hospitalier régional de Rimouski, Rimouski, Quebec, CanadaView further author information
,
Sathish Gopalakrishnanh Health Sciences North, Sudbury, Ontario, CanadaView further author information
,
Sarah-Jane Bulli Medical Affairs, AbbVie Corporation, St-Laurent, Quebec, CanadaView further author information
,
Pierre-André Fournieri Medical Affairs, AbbVie Corporation, St-Laurent, Quebec, CanadaView further author information
,
Adi J. Klil-Drorii Medical Affairs, AbbVie Corporation, St-Laurent, Quebec, CanadaView further author information
,
Annette E. Hayj Queen’s University, Kingston, Ontario, CanadaView further author information
,
Sue Robinsonk Dalhousie University, and QEII Health Sciences Centre, Halifax, Nova Scotia, CanadaView further author information
&
Carolyn Owenl Tom Baker Cancer Centre, Calgary, Alberta, CanadaView further author information
 show all
Pages 609-617 | Received 20 Sep 2023, Accepted 30 Dec 2023, Published online: 18 Jan 2024

References

  • Health Canada. 2016 21 January. VENCLEXTA® (venetoclax tablets) Product Monograph. AbbVie Corporation https://pdf.hres.ca/dpd_pm/00059710.PDF. Accessed 2021 21 January.
  • Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–778. doi:10.1016/S1470-2045(16)30019-5
  • Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854. doi:10.1056/NEJMra0904569
  • Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–144. doi:10.1200/JCO.1998.16.1.139
  • Holzner B, Kemmler G, Kopp M, et al. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol. 2004;72(6):381–389. doi:10.1111/j.1600-0609.2004.00233.x
  • Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322. doi:10.1056/NEJMoa1513257
  • Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120. doi:10.1056/NEJMoa1713976
  • Hampel PJ, Rabe KG, Call TG, et al. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022;12(9):124. doi:10.1038/s41408-022-00721-6
  • Hampel PJ, Ding W, Call TG, et al. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019;60(11):2712–2719. doi:10.1080/10428194.2019.1602268
  • Ferrarini I, Gandini F, Zapparoli E, et al. Two distinct clinical patterns of ibrutinib-to-venetoclax transition in relapsed chronic lymphocytic leukemia patients. Curr Oncol. 2022;29(4):2792–2797. doi:10.3390/curroncol29040227
  • Gribben JG. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2020;188(6):844–851. doi:10.1111/bjh.16345

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.